| P50 | author | Srdan Verstovsek | Q64026418 |
| P2093 | author name string | Prithviraj Bose | |
| P2860 | cites work | Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2 | Q24568313 |
| | CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients | Q27852820 |
| | Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis | Q27853043 |
| | Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib | Q27853179 |
| | A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera | Q28241887 |
| | Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis | Q29614337 |
| | A gain-of-function mutation of JAK2 in myeloproliferative disorders | Q29618851 |
| | CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons | Q29998841 |
| | Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis | Q33370690 |
| | Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele | Q33385124 |
| | Identification during the follow-up of time-dependent prognostic factors for the competing risks of death and blast phase in primary myelofibrosis: a study of 172 patients | Q33388851 |
| | Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients | Q33392291 |
| | DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status | Q33393245 |
| | Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study | Q33394025 |
| | JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis | Q33399977 |
| | The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis | Q42385052 |
| | LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations | Q42931701 |
| | Taxing sugar-sweetened beverages | Q43180928 |
| | JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis. | Q43199526 |
| | MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients | Q44008600 |
| | Mutations and prognosis in primary myelofibrosis | Q44429606 |
| | Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms. | Q45905329 |
| | Risk factors for leukemic transformation in patients with primary myelofibrosis | Q46650489 |
| | The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates | Q46753346 |
| | Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not. | Q47935045 |
| | V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. | Q50747615 |
| | Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients. | Q51025938 |
| | How I treat myelofibrosis. | Q51036404 |
| | Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. | Q51761197 |
| | Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. | Q53096529 |
| | Improving survival trends in primary myelofibrosis: an international study. | Q53126695 |
| | Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients. | Q53147067 |
| | Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. | Q53166045 |
| | International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis. | Q53184187 |
| | Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival. | Q53184342 |
| | Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence. | Q53298023 |
| | Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis. | Q54282700 |
| | CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis. | Q54303948 |
| | Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact. | Q54374932 |
| | Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. | Q54426186 |
| | Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis. | Q54504237 |
| | EZH2 mutational status predicts poor survival in myelofibrosis. | Q54560112 |
| | The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients | Q58455624 |
| | What are RBC-transfusion-dependence and -independence? | Q59620003 |
| | Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression | Q61050089 |
| | A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). | Q61050093 |
| | Thrombosis in primary myelofibrosis: incidence and risk factors | Q61050096 |
| | A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis | Q61758719 |
| | The Reticulin Content of Bone Marrow in Acute Leukaemia in Adults | Q66971031 |
| | New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment | Q79802927 |
| | Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival | Q80542642 |
| | Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases | Q80607021 |
| | Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment | Q80866784 |
| | Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution | Q81528363 |
| | p53 lesions in leukemic transformation | Q83352019 |
| | SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival | Q84962229 |
| | Changing myelofibrosis's natural course at last | Q87486555 |
| | Circulating hematopoietic progenitor cells in essential thrombocythemia versus prefibrotic/early primary myelofibrosis | Q87547449 |
| | Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms | Q95779600 |
| | A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis | Q33399980 |
| | Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis | Q33411211 |
| | Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study | Q33412856 |
| | Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis | Q33416223 |
| | Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. | Q33419957 |
| | A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis | Q33425581 |
| | Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis | Q33697252 |
| | Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls | Q33843390 |
| | Somatic mutations of calreticulin in myeloproliferative neoplasms | Q34039270 |
| | Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked | Q34166617 |
| | Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS | Q34451630 |
| | Revised international prognostic scoring system for myelodysplastic syndromes | Q34639717 |
| | JAK2 V617F genotype is a strong determinant of blast transformation in primary myelofibrosis | Q34652224 |
| | MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia | Q34770384 |
| | IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F | Q35835653 |
| | A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis | Q36708975 |
| | The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course | Q36788138 |
| | The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms | Q36843673 |
| | Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms | Q36946576 |
| | Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. | Q37127245 |
| | Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis | Q37163487 |
| | Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. | Q37163590 |
| | Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. | Q37900078 |
| | Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. | Q37934479 |
| | Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia | Q38087202 |
| | An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms | Q38179853 |
| | Novel myelofibrosis treatment strategies: potential partners for combination therapies | Q38216827 |
| | Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) | Q38242725 |
| | Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matter | Q38246160 |
| | Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms | Q38419665 |
| | Myeloproliferative Neoplasms: A Contemporary Review | Q38548597 |
| | Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group | Q38570614 |
| | Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms | Q39482201 |
| | JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. | Q40181513 |
| | Inactivation of the p53 pathway in retinoblastoma. | Q42152329 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 681-692 | |
| P577 | publication date | 2015-12-30 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | The evolution and clinical relevance of prognostic classification systems in myelofibrosis | |
| P478 | volume | 122 | |